Glucosamine treats the underlying cause of osteoarthritis and the therapeutic effect can only be seen after 2-3 weeks. Therefore, it is advisable to take an analgesic and anti-inflammatory drug if required during the first 2-3 weeks of therapy with glucosamine. Administration during the first three months of pregnancy must be avoided. Safety and effectiveness have not been established in children therefore children should avoid using glucosamine. The administration in patients with severe hepatic or renal insufficiency should be made under medical supervision. Derived from seafood, therefore should not be given to patients who are allergic to shellfish. A doctor should be consulted in order to exclude the presence of other joint conditions/diseases for which an alternative treatment should be considered. Glucosamine may affect insulin sensitivity and glucose tolerance. Patients with type 2 diabetes and patients who are overweight or having glucose tolerance problems should monitor their blood sugar levels regularly when taking any products containing glucosamine. Unsuitable for phenylketonurics.
Effects on Ability to Drive and Use Machines: No effects on the ability to drive or to operate machines are expected.
Use in Pregnancy and Lactation: Available evidence is inconclusive or inadequate for use in pregnant or lactating mothers. Until more information is available, this product should only be used under medical supervision in pregnancy and lactating mother if the potential benefit to the mother justifies the potential risk to the fetus. Administration during the first 3 months of pregnancy must be avoided.